Cancer NetworkOriginal article
<![CDATA[Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials]]>
Data ReadoutpositivedaratumumabVCdPositive
AI Analysis
Summary
Pooled analysis of AMY2009 and AMY3001 trials demonstrated that daratumumab plus VCd achieved hematologic complete responses in patients with cardiac-involved AL amyloidosis.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
pooled analysis of AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis
Importance:6/10
Sentiment:
0.70
daratumumabAL amyloidosiscardiac involvementclinical trial datahematologic response
Read the original article
Published by Cancer Network on September 24, 2026 5:00 PM